2C-H Stats & Data
[Cl-].NCCc1cc(OC)ccc1OC.[H+]PJMQBIMLDBAWRK-UHFFFAOYSA-NPharmacology
DrugBankDescription
2C-H was first synthesized in 1932 by Johannes S. Buck. It is used as a precursor in the synthesis of other substituted phenethylamines such as 2C-B, 2C-I, and 2C-N. 2C-H has been found in trace amounts by the DEA's south central laboratory in tablets that were suspected of containing MDMA.
Mechanism of Action
There is no record of 2C-H trials in humans, as it would likely be destroyed by monoamine oxidase enzymes before causing any significant psychoactive effects. In the book PiHKAL, Alexander Shulgin lists both the dosage and duration of 2C-H effects as unknown. Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-H.
Protein Binding
2C-H exhibits agonist activity in vitro at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization. 2C-H was found to be inactive in NCI In Vivo Anticancer Drug Screens for tumor model L1210 Leukemia. It was found to be an active Alpha-1 adrenergic receptor agonist in rabbit ear arteries. It has binding affinity towards 5-HT2C and 5-HT2A receptors in rats. It features competitive antagonist activity at 5-HT serotonin receptor in Sprague-Dawley rat stomachs. It exhibits binding affinity against rat 5-hydroxytryptamine 2C receptors using mesulergine as a radioligand.
Effect Profile
Curated + 1 ReportsStrong auditory effects with moderate visuals and body load
Strong anxiety/jitters with moderate stimulation and euphoria